ClinicalTrials.gg
CompletedNCT01100112Updated Nov 29, 2019Results posted

(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets

A Phase 3 interventional study of Budesonide in Colitis, Ulcerative, sponsored by Bausch Health Americas, Inc.. Completed at 15 sites in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies testing budesonide in Colitis, Ulcerative — 1 open to participants now, 1 under way, none of them phase 3. Budesonide · Colitis, Ulcerative.

Enrollment
8th of 10
61 · median 183
Started
2010
the only one that year
Phase 3
6 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
5 of 10
Bausch Health Americas, Inc.

Among the 10 studies testing budesonide in Colitis, Ulcerative, this one is the 8th largest by enrollment, is the only one that started in 2010, is one of 6 in phase 3, and was the 5th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 10 studies testing budesonide in Colitis, Ulcerative is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing budesonide in Colitis, Ulcerative, or all of them as a file.
02

Study summary

Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01 (parent study [NCT00679432]).

Read the detailed description

Patients who complete the parent study and who do not achieve clinical remission will be eligible to receive 8 weeks of open-label treatment with Budesonide-MMX 9mg if they satisfy the entry criteria for this study.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • ulcerative colitis
  • Budesonide
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18 to 74 years of age, who are able to understand and voluntarily provide written
  • Completed all Final Visit assessments for study CB-01-02/01 (NCT00679432) and are not in clinical remission
  • Diagnosis of ulcerative colitis of mild to moderate severity with an Ulcerative Colitis Disease Activity Index (UCDAI) \<or= 10 according to Sutherland
  • Females of must have had a serum pregnancy test performed at the Final Visit of the parent study, and must use an acceptable method throughout the treatment period. Female subjects must also not be actively breast-feeding through the entire study period.
  • Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
  • Ability to co-operate with the investigator and to comply with the requirements of the entire study

Exclusion criteria

Exclusion Criteria:

  • Did not complete study CB-01-02/01
  • Achieved clinical remission in study CB-01-02/01
  • Patients with severe ulcerative colitis (UCDAI >10)
  • Patients with infectious colitis
  • Evidence or history of toxic megacolon
  • Severe anemia, leucopenia, or granulocytopenia
  • Use of agents in the last 8 weeks before the study
  • use of anti-tumor necrosis factor alpha agents in the last three months
  • Concomitant use of any rectal preparation for the treatment of ulcerative colitis
  • Concomitant use of antibiotics
  • Concurrent use of cytochrome P-450 3A4 () inducers and CYP3A4 inhibitors.
  • Patients with verified, presumed of expected pregnancy or ongoing lactation
  • Patients with liver cirrhosis, or evident hepatic or renal disease or insufficiency and/or severe impairment of the bio-humoral parameters (i.e., 2x for , aspartate aminotransferase, gamma-glutamyl transpeptidase, or creatinine)
  • Patients with severe disease(s) in other organs of systems
  • Patients with local of systemic complications of other pathological states requiring a therapy with and/or immunosuppressive agents
  • Patients diagnosed with Type 1 diabetes
  • Patients diagnosed with or with a family history of glaucoma
  • Patients with known , , or with (HIV), according to the local privacy policy
  • Any other medical condition that in the principal investigator's opinion would make the administration of the study drug or study procedures hazardous to the subject or obscure the interpretation of adverse events
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Budesonide

    Budesonide-MMX 9 mg tablet

    Drug: Budesonide

Interventions

  • One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.

06

What researchers measure

Primary outcomes

  1. The Percentage of Patients Achieving Clinical Remission

    The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of \< or = 1 with a score of 0 for both rectal bleeding and stool frequency, and \> or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance). The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum \[worst\] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = \> 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.

    Time frame: At the end of the 8 week treatment period

Secondary outcomes

  1. The Secondary Efficacy Endpoint is Clinical Improvement

    The secondary efficacy endpoint is clinical improvement, defined as a drop in the Ulcerative Colitis Disease Activity Index score of \> or = 3 points from baseline.

    Time frame: After 8 weeks treatment period

  2. Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.

    Safety will be assessed by evaluating SAEs and AEs. The outcome measure data are the numbers of patients who experienced SAEs or other nonserious AEs.

    Time frame: Throughout the 8 week treatment period

  3. Endoscopic Improvement

    Greater or equal to a 1 point improvement in the mucosal appearance subscore of the ulcerative colitis disease activity index (UCDAI), from baseline to week 8. The UCDAI mucosal appearance subscore is graded as follows: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.

    Time frame: 8 weeks

07

Results

Posted Jun 5, 2014
Limitations and caveats
This was an open label study. There was no reference therapy for statistical analysis.

Participant flow

Recruited from February 2010 to July 2010

Participant flow — Overall Study
MilestoneBudesonide
Started60
Completed52
Not completed8

Outcome measures

PrimaryThe Percentage of Patients Achieving Clinical Remission

The primary efficacy endpoint is clinical remission at 8 weeks, defined as a Ulcerative Colitis Disease Activity Index score of \< or = 1 with a score of 0 for both rectal bleeding and stool frequency, and \> or = 1 point reduction from baseline in endoscopy score, without any sign of mucosal friability (a score of 0 for mucosal appearance). The UCDAI has 4 components. Each component is scored on scale of 0 to 3 (total maximum \[worst\] score = 12). Definitions of component scores are as follows: stool frequency: 0 = normal frequency, 1 = 1 - 2 stools per day greater than normal frequency, 2 = 3 - 4 stools per day greater than normal frequency, and 3 = \> 4 stools per day greater than normal frequency; rectal bleeding: 0 = none, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood; physician's rating of disease activity: 0 = normal, 1 = mild, 2 = moderate, 3 = severe; mucosal appearance: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.

Time frame:
At the end of the 8 week treatment period
Reported as:
Number · percentage of patients
The Percentage of Patients Achieving Clinical Remission
percentage of patientsBudesonide
The Percentage of Patients Achieving Clinical Remission25
SecondaryThe Secondary Efficacy Endpoint is Clinical Improvement

The secondary efficacy endpoint is clinical improvement, defined as a drop in the Ulcerative Colitis Disease Activity Index score of \> or = 3 points from baseline.

Time frame:
After 8 weeks treatment period
Reported as:
Number · percentage of patients
The Secondary Efficacy Endpoint is Clinical Improvement
percentage of patientsBudesonide
The Secondary Efficacy Endpoint is Clinical Improvement26.7
SecondarySafety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.

Safety will be assessed by evaluating SAEs and AEs. The outcome measure data are the numbers of patients who experienced SAEs or other nonserious AEs.

Time frame:
Throughout the 8 week treatment period
Reported as:
Number · participants
Safety Evaluations: the Numbers of Patients Who Experience Serious Adverse Events (SAEs) or Other Nonserious Adverse Events (AEs) During the Course of the Study.
participantsBudesonide
Serious Adverse Events2
Other non-serious adverse events29
SecondaryEndoscopic Improvement

Greater or equal to a 1 point improvement in the mucosal appearance subscore of the ulcerative colitis disease activity index (UCDAI), from baseline to week 8. The UCDAI mucosal appearance subscore is graded as follows: 0 = normal, 1 = mild friability, 2 = moderate friability, 3 = exudation, spontaneous bleeding.

Time frame:
8 weeks
Reported as:
Number · percentage of patients
Endoscopic Improvement
percentage of patientsBudesonide
Endoscopic Improvement40

Adverse events

Collected over 56 day ± 2 day (study duration) + 30 day safety followup period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Budesonide—2/60 (3.3%)29/60 (48.3%)
Most frequent serious events
Most frequent serious events
EventBudesonide
Colitis ulcerativeGastrointestinal disorders1/60
Endometrial hyperplasiaReproductive system and breast disorders1/60
Most frequent other events
Most frequent other events
EventBudesonide
Blood cortisol decreasedInvestigations9/60
Urinary tract infectionInfections and infestations7/60
CushingoidEndocrine disorders3/60
DiarrhoeaGastrointestinal disorders2/60
AstheniaGeneral disorders2/60
PyrexiaGeneral disorders2/60
Blood glucose decreasedInvestigations2/60
Blood potassium increasedInvestigations2/60

Baseline characteristics

All patients who received at least 1 dose of study drug were considered Evaluable patients. Total evaluable population was 60.

Age, Categorical
Age, Categorical(Participants)Budesonide
<=18 years0
Between 18 and 65 years60
>=65 years0
Age, Continuous
Age, Continuous(years)Budesonide
Mean40.3 ± 11.41
Sex: Female, Male
Sex: Female, Male(Participants)Budesonide
Female19
Male41
Region of Enrollment
Region of Enrollment(participants)Budesonide
India60
08

Study locations

15 sites
  • Santarus Clinical Investigational Site 9001
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9009
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9012
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9016
    Andhra Pradesh, India
  • Santarus Clinical Investigational Site 9006
    Assam, India
  • Santarus Clinical Investigational Site 9007
    Gujarat, India
  • Santarus Clinical Investigational Site 9004
    Karnataka, India
  • Santarus Clinical Investigational Site 9015
    Karnataka, India
  • Santarus Clinical Investigational Site 9003
    Kerala, India
  • Santarus Clinical Investigational Site 9002
    Maharashtra, India
  • Santarus Clinical Investigational Site 9008
    Maharashtra, India
  • Santarus Clinical Investigational Site 9013
    Maharashtra, India
  • Santarus Clinical Investigational Site 9018
    Rajasthan, India
  • Santarus Clinical Investigational Site 9005
    Tamil Nadu, India
  • Santarus Clinical Investigational Site 9014
    Uttar Pradesh, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Jul 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 11 months after primary completion. A results delay was requested in Feb 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2010
First posted
Apr 8, 2010
Start
Feb 2010
Primary completionActual
Jul 2010
CompletionActual
Aug 2010
Results delay requested
Feb 9, 2012
Results first posted
Jun 5, 2014
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01100112
Collaborators
Cosmo Technologies Ltd
Responsible party
Sponsor
First posted
Apr 8, 2010
Start date
Feb 2010
Primary completion
Jul 2010
Completion
Aug 2010
Results posted
Jun 5, 2014
Last update
Nov 29, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion